Pharmacokinetics: Omeprazole are enteric-coated to protect them from premature activation by gastric acid. After absorption in the duodenum, they are transported to the acid parietal cell canaliculus, where they are converted to active species. Metabolites of these agents are excreted in urine and feces.
Treatment of duodenal and gastric ulcer. Also used for Helicobacter pylori eradication in peptic ulcer disease, reflux esophagitis and Zollinger-Ellison syndrome. Patients considered to be at risk of aspiration of gastric contents during general anesthesia/acid aspiration prophylaxis.
Reflux Esophagitis: Usual Dose: 20-40 mg once daily.
Maintenace Dose: Therapy can be continued with 20 mg once daily.
Zollinger-Ellison Syndrome: Initial Recommended Dose: 60 mg once daily, but doses of 20-120 mg daily may be used.
Before giving omeprazole to patients with gastric ulcers, the possibility of malignancy should be excluded since omeprazole may mask symptoms and delay diagnosis.
Omeprazole are generally well tolerated. The adverse effects reported frequently with omeprazole have been diarrhea, constipation, skin rashes, nausea and headache.
Omeprazole interferes in the oxidation of warfarin, phenytoin, diazepam and cyclosporine.
Store at temperatures not exceeding 30°C.
A02BC01 - omeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).